Here is the design of a clinical trial:

Official Title: Cyclophosphamide Added to Corticosteroid in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Placebo-controlled Randomized Trial

Included conditions:
- Idiopathic Pulmonary Fibrosis

Study Armgroups:
- {'label': 'Corticosteroid with placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.\n\nAll patients will receive non experimental medication with high dose of corticosteroid.', 'interventionNames': ['Drug: Placebo', 'Drug: Corticosteroid (prednisolone)']}
- {'label': 'Corticosteroid associated with Cyclophosphamide', 'type': 'EXPERIMENTAL', 'description': 'Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.\n\nAll patients will receive non experimental medication with high dose of corticosteroid.\n\nIntravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2', 'interventionNames': ['Drug: Cyclophosphamide', 'Drug: Corticosteroid (prednisolone)']}

Interventions:
- {'type': 'DRUG', 'name': 'Cyclophosphamide', 'description': 'Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.\n\nIntravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2', 'armGroupLabels': ['Corticosteroid associated with Cyclophosphamide']}
- {'type': 'DRUG', 'name': 'Placebo', 'description': 'Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.', 'armGroupLabels': ['Corticosteroid with placebo'], 'otherNames': ['Control group']}
- {'type': 'DRUG', 'name': 'Corticosteroid (prednisolone)', 'description': 'All patients will receive non experimental medication with high dose of corticosteroid.', 'armGroupLabels': ['Corticosteroid associated with Cyclophosphamide', 'Corticosteroid with placebo'], 'otherNames': ['Both groups']}

Primary Outcomes:
- {'measure': '"Early" survival', 'description': 'All cause of mortality at 3 months', 'timeFrame': '3 months'}

Please estimate the sample size based on the assumption: 
Alpha = 5%, power = 80%, two-sided tests, and a dropout rate within the limit of 10% of the initial number of patients needed.
Sample size
          Reviewing all the series reported between 1993 and 2006 revealed a 3-month mortality rate of 67.1% (95% confidence interval [CI]: 56.2â76.5) [5].
          We thus hypothesize that the 3-month mortality rate with methylprednisolone pulse dosing will be 67%, decreasing to 42% after adding CYC. Given that alphaâ=â5%, powerâ=â80%, and two-sided tests will be applied, 60 subjects per group are needed. In case of dropouts, additional patients will be included within the limit of 10% of the initial number of patients needed.
          Therefore, 120 patients should be recruited in a period of 24âmonths and that correspond to 13% of the expected new patients.